Calcilytix Therapeutics, Inc., A Bridgebio Company
Clinical trials sponsored by Calcilytix Therapeutics, Inc., A Bridgebio Company, explained in plain language.
Now part of
BridgeBio Pharma, Inc.
BBIO
NASDAQ
A biotech company developing therapies for calcification-related diseases, owned by BridgeBio.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.